Venus Remedies Ltd Gains 4.11%: 5 Key Factors Driving the Week’s Momentum

13 July: Upper Circuit Triggered Amid Strong Buying Pressure

Venus Remedies Ltd surged 5.00% on 13 July 2026, closing at ₹1,821.85 after hitting its upper circuit limit of ₹1,805.40 intraday. This gain was remarkable given the broader market’s near-flat performance, with the Sensex rising a mere 0.01% to 36,508.75. The stock’s trading range of ₹1,715.00 to ₹1,805.40 reflected strong upward momentum, supported by a turnover of approximately ₹5.67 crore on volume of 31,825 shares.

Despite the price surge, the weighted average price suggested cautious profit-taking as the stock approached the circuit limit. Delivery volumes declined by 44.25% compared to the five-day average, indicating some speculative demand rather than sustained accumulation. Nevertheless, Venus Remedies outperformed its Pharmaceuticals & Biotechnology sector peers, which declined 0.35% that day.

Technically, the stock traded above all key moving averages, signalling a strong bullish trend. The regulatory freeze following the upper circuit hit indicated unfilled demand, suggesting potential for further gains once restrictions eased.

14 July: Continued Momentum with Upper Circuit and Valuation Re-rating

On 14 July, Venus Remedies again hit the upper circuit, closing at ₹1,912.90, a 5.00% gain from the previous day’s close. This performance outpaced the Pharmaceuticals & Biotechnology sector’s 0.63% rise and contrasted with the Sensex’s 0.67% decline to 36,265.57. The stock’s volume of 35,052 shares and turnover of ₹6.59 crore reflected heightened investor enthusiasm, with delivery volumes surging 337.28% over the five-day average, signalling strong conviction among buyers.

Technical positioning remained favourable, with the stock trading above all major moving averages and recording gains for four consecutive sessions, accumulating an 11.66% return over this period. The regulatory freeze again capped price movement but highlighted substantial unfilled demand.

Simultaneously, valuation metrics shifted from fair to expensive. The price-to-earnings ratio rose to 23.69 and price-to-book value to 3.67, reflecting elevated investor expectations. Despite this, operational metrics remained strong, with ROCE at 21.23% and ROE at 15.49%, supporting the premium valuation. Peer comparisons showed Venus Remedies’ valuation was moderate relative to some sector players trading at much higher multiples.

14 July: Upgrade to Buy Rating on Strong Technicals and Financials

MarketsMOJO upgraded Venus Remedies Ltd from a Hold to a Buy rating on 14 July 2026, reflecting improved technical indicators and robust financial performance. The stock’s technical grade shifted to bullish, supported by positive MACD signals on weekly and monthly charts, bullish Bollinger Bands, and favourable moving averages. Despite some mixed signals from RSI and volume indicators, the overall momentum favoured continued gains.

Financially, the company reported strong quarterly results for Q4 FY25-26, with net sales reaching ₹259.40 crores and PBDIT at ₹63.42 crores. Operating profit grew at 45.72% annually, while net profit soared 126.19%, demonstrating operational efficiency and margin expansion. The company remained net-debt free, enhancing financial stability.

Institutional investors increased their stake by 0.72% to 4%, signalling confidence in the company’s prospects. The stock’s year-to-date return of 149.40% and one-year return of 301.87% vastly outpaced the Sensex’s losses, underscoring its market-beating performance.

15 July: Minor Correction Amid Mixed Technical Signals

On 15 July, Venus Remedies experienced a mild correction, closing at ₹1,889.70, down 1.21% from the previous day. This pullback occurred despite the Sensex gaining 0.31% to 36,378.34. The volume declined to 4,043 shares, reflecting reduced trading activity. The correction aligned with some mixed technical signals, including a bearish monthly RSI and mildly bearish weekly Dow Theory readings, suggesting short-term hesitancy.

This pause in the rally may represent profit-taking or consolidation after the strong gains earlier in the week. Investors should monitor volume and price action for signs of renewed momentum or further correction.

16-17 July: Stabilisation and Modest Gains to Close the Week

On 16 July, the stock declined sharply by 4.78% to ₹1,799.45 on low volume of 2,310 shares, while the Sensex slipped 0.13%. This drop reflected some profit-booking and cautious sentiment following the prior week’s rally. However, on 17 July, Venus Remedies rebounded modestly by 0.39% to close at ₹1,806.45, supported by a slight increase in volume to 1,664 shares. The Sensex also recovered, gaining 0.48% to 36,505.40.

This stabilisation suggests that the stock found support near ₹1,800 levels, ending the week with a net gain of 4.11% and outperforming the flat Sensex. The week’s price action highlights a balance between strong technical momentum and valuation caution.

Key Takeaways

Strong Technical Momentum: Venus Remedies demonstrated robust bullish momentum, hitting upper circuit limits on two consecutive days and trading above all key moving averages. The upgrade to a Buy rating on 14 July reflects this positive technical shift.

Exceptional Weekly Outperformance: The stock gained 4.11% over the week, significantly outperforming the flat Sensex. This outperformance was driven by strong buying interest and positive quarterly financial results.

Valuation Re-rating: The shift from fair to expensive valuation metrics, including a P/E of 23.69 and P/B of 3.67, signals elevated price levels. While justified by strong operational metrics and growth, this warrants caution regarding near-term upside.

Volume and Delivery Trends: Delivery volumes surged notably on 14 July, indicating genuine investor conviction. However, lower volumes and some bearish volume indicators later in the week suggest the rally may face consolidation or profit-taking.

Micro-Cap Risks and Market Position: As a micro-cap stock, Venus Remedies carries inherent liquidity and volatility risks. The recent rating upgrade balances optimism with prudence, reflecting both growth potential and valuation concerns.

Conclusion

Venus Remedies Ltd’s week was characterised by strong price gains, technical momentum, and a significant upgrade in analyst sentiment. The stock’s ability to hit upper circuit limits twice and outperform the Sensex amid mixed market conditions underscores its resilience and investor appeal. However, the shift to an expensive valuation grade and mixed volume signals suggest that investors should remain vigilant for potential volatility or consolidation phases.

Overall, the week’s developments highlight Venus Remedies as a noteworthy performer in the Pharmaceuticals & Biotechnology sector, combining solid fundamentals with technical strength. The upgrade to a Buy rating by MarketsMOJO reflects balanced optimism, recognising both the company’s growth trajectory and the need for careful risk management in a micro-cap context.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today